AstraZeneca PLC (AZN) Debt to Equity Ratio: 0.61
Is AstraZeneca PLC’s debt to equity ratio high or low?
AstraZeneca PLC's debt to equity ratio of 0.61 is 26% below its 5-year average of 0.83, near the low end of its 5-year range (0.61–1.30).
As of Friday, June 12, 2026. 9.63% below its 12-month average of 0.68.
AZN Debt to Equity Ratio Chart
AZN Average Debt to Equity Ratio Chart
AZN Current vs Average Debt to Equity Ratio Chart
AZN Debt to Equity Ratio Metrics
DEBT TO EQUITY RATIO
0.61
DEBT TO EQUITY RATIO AVG TTM
0.68
DEBT TO EQUITY RATIO AVG 3Y
0.72
DEBT TO EQUITY RATIO AVG 5Y
0.83
DEBT TO EQUITY RATIO AVG 10Y
1.00
DEBT TO EQUITY RATIO AVG 15Y
0.83
DEBT TO EQUITY RATIO AVG 20Y
0.75
CURRENT VS TTM AVG
-9.63%
CURRENT VS 3Y AVG
-14.98%
CURRENT VS 5Y AVG
-26.06%
CURRENT VS 10Y AVG
-39.00%
CURRENT VS 15Y AVG
-26.28%
CURRENT VS 20Y AVG
-18.56%
AZN Competitors' Debt to Equity Ratio
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $282.69B | 0.61 | 0.68 | 0.72 | 0.83 |
| Merck & Co., Inc. (MRK) | $298.29B | 0.96 | 0.90 | 0.86 | 0.95 |
| UnitedHealth Group Incorporated (UNH) | $368.30B | 0.83 | 0.83 | 0.79 | 0.74 |
| Amgen Inc. (AMGN) | $191.09B | 6.31 | 8.27 | 9.39 | 7.67 |
| Thermo Fisher Scientific Inc. (TMO) | $176.77B | 0.76 | 0.71 | 0.76 | 0.76 |
| AbbVie Inc. (ABBV) | $397.12B | -21.12 | 13.10 | 8.74 | 8.32 |
| Gilead Sciences, Inc. (GILD) | $156.28B | 1.09 | 1.23 | 1.19 | 1.29 |
| Abbott Laboratories (ABT) | $156.15B | 0.29 | 0.30 | 0.38 | 0.44 |
| Pfizer Inc. (PFE) | $149.18B | 0.78 | 0.77 | 0.68 | 0.63 |
| Intuitive Surgical, Inc. (ISRG) | $146.23B | 0.02 | 0.01 | 0.01 | 0.01 |
Financial Health
Debt/Equity
0.61
Current Ratio
0.94
AstraZeneca PLC Debt to Equity Ratio Formula & Definition
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC Debt to Equity Ratio FAQ
- What is the debt to equity ratio for AstraZeneca PLC (AZN)?
- The debt to equity ratio for AZN stock is 0.61.
- Is AstraZeneca PLC's debt to equity ratio high or low?
- AstraZeneca PLC's debt to equity ratio of 0.61 is 26% below its 5-year average of 0.83, near the low end of its 5-year range (0.61–1.30).
- What is the TTM average debt to equity ratio for AstraZeneca PLC (AZN)?
- The TTM average debt to equity ratio for AZN stock is 0.68.
- What is the 3Y average debt to equity ratio for AstraZeneca PLC (AZN)?
- The 3Y average debt to equity ratio for AZN stock is 0.72.
- What is the 5Y average debt to equity ratio for AstraZeneca PLC (AZN)?
- The 5Y average debt to equity ratio for AZN stock is 0.83.
- What is the 10Y average debt to equity ratio for AstraZeneca PLC (AZN)?
- The 10Y average debt to equity ratio for AZN stock is 1.00.
- What is the 15Y average debt to equity ratio for AstraZeneca PLC (AZN)?
- The 15Y average debt to equity ratio for AZN stock is 0.83.
- What is the 20Y average debt to equity ratio for AstraZeneca PLC (AZN)?
- The 20Y average debt to equity ratio for AZN stock is 0.75.
AstraZeneca PLC Debt to Equity Ratio History
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-12-31 | 0.61 |
| 2024-12-31 | 0.74 |
| 2023-12-31 | 0.73 |
| 2022-12-31 | 0.79 |
| 2021-12-31 | 0.78 |
| 2020-12-31 | 1.30 |
| 2019-12-31 | 1.39 |
| 2018-12-31 | 1.53 |
| 2017-12-31 | 1.19 |
| 2016-12-31 | 1.13 |
| 2015-12-31 | 0.81 |
| 2014-12-31 | 0.55 |
| 2013-12-31 | 0.45 |
| 2012-12-31 | 0.43 |
| 2011-12-31 | 0.40 |
| 2010-12-31 | 0.41 |
| 2009-12-31 | 0.55 |
| 2008-12-31 | 0.74 |
| 2007-12-31 | 1.03 |
| 2006-12-31 | 0.08 |
| 2005-12-31 | 0.09 |
| 2004-12-31 | 0.09 |
| 2003-12-31 | 0.03 |
| 2002-12-31 | 0.08 |
| 2001-12-31 | 0.10 |
| 2000-12-31 | 0.09 |
| 1999-12-31 | 0.11 |
| 1998-12-31 | 0.25 |
| 1997-12-31 | 0.33 |
| 1996-12-31 | 0.36 |
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot